Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Sees No Future In NicOx Glaucoma Candidate After Failure In Japanese Phase II Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Collaboration turns to diabetic retinopathy after Pfizer backs away from PF-03187207 development.

You may also be interested in...



NicOx Buys Back Glaucoma Drug Rights From Pfizer

The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.

NicOx Buys Back Glaucoma Drug Rights From Pfizer

The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.

BIO CEO & Investor Conference In Brief

CytRx looks to put arimoclomal on track: CytRx plans to submit a toxicology report to FDA in the second quarter to facilitate the return of its Phase II candidate arimoclomal for Amyotrophic Lateral Sclerosis to the clinic, VP-Business Development David Haen said during the BIO CEO & Investor Conference in New York Feb. 9-10. The drug was put on clinical hold by FDA in January 2008 due to toxicology concerns stemming from an earlier rat study. CytRx conducted another study to address FDA's concerns. Arimoclomal is one of the firm's key internal assets; the firm is seeking to partner the drug. "We have had this cloud, this clinical hold, but we do expect it to be resolved," Haen said

Related Content

Topics

UsernamePublicRestriction

Register

PS068270

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel